HOME >> BIOLOGY >> NEWS
The PSA bounce Does it have clinical significance?

Using the largest known prostate cancer data set of patients treated solely with external-beam radiation in the U.S., radiation oncologists have examined the "PSA bounce" phenomenon and determined that it is not an indicator that men will die of prostate cancer any sooner than those men who do not experience a bounce. That is the result of a multi-institutional analysis presented today at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Atlanta, Ga.

The PSA (prostate-specific antigen) test is a blood test used for routine prostate cancer screening. The "PSA bounce" is a rise and then decline in the PSA level following radiation treatment for prostate cancer. The bounce phenomenon occurs in a third to half of men treated with radiation for prostate cancer. Urologists, radiation and medical oncologists have struggled with what a bouncing PSA means for a patient's prognosis, and how or if to offer further treatment.

"Because a steady rise in PSA can mean that cancer has recurred, physicians often interpret a bounce as the possibility that the cancer may still exist after treatment," explained Eric M. Horwitz, M.D., clinical director of the radiation oncology department at Fox Chase Cancer Center and lead author of the study. "Some physicians prescribe hormonal therapy in this situation, but hormones can have significant side effects for the patient, and may not be clinically necessary. For these reasons, it's important to develop clear guidelines."

In this retrospective analysis, data were gathered from the records of 4,839 men treated only with external-beam radiation between 1986 and 1995 at nine institutions throughout the US. The median follow-up was 6.3 years. Treatment during this time period consisted primarily of conventional radiation therapy, a lower dose than is generally used at academic cancer centers today, although some patients were treated with 3D conformal radiation therapy. In thi
'"/>

Contact: Colleen Kirsch
colleen.kirsch@fccc.edu
215-306-1211
Fox Chase Cancer Center
6-Oct-2004


Page: 1 2

Related biology news :

1. HIV-1 kills immune cells in the gut that may never bounce back
2. Phytoplankton bounce back from abrupt climate change
3. Fat kids can bounce back to normal blood pressure
4. Preclinical study links gene to brain aneurysm formation
5. Gene variant is associated with brain anatomy, clinical course of ADHD
6. New joint replacement material developed at MGH put to first clinical use
7. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
8. From clinical cancer research: rethinking therapeutic cancer vaccine trials
9. Manganese levels increase in scrapie-infected sheep before clinical symptoms develop
10. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
11. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market Intelligence ... Biometrics and Digital Identity".  Acuity characterizes 2017 as ... when increased adoption reflects a new understanding of ... "Biometrics and digital identity are often perceived ... Maxine Most , Principal of Acuity Market intelligence. ...
(Date:1/24/2017)...  It sounds simple and harmless—an electronic sensor ... signs and alerts parents on their smart phones ... drops. But pediatric experts argue that such devices ... evidence of medical benefits, especially to healthy babies. ... parents of healthy babies, promising peace of mind ...
(Date:1/19/2017)... and PUNE, India , January 19, 2017 /PRNewswire/ ... titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," the ... at a CAGR of 9.6% from 2016 to 2022. In 2015, ... to high-level security for both public and private sectors. ... ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as organic, ... label organic services. , The first organic product is Organic 18 Percent Layer Feed, ... Marketing, which owns the facility. , Catalyst already has received the Safe Feed/Safe ...
(Date:2/24/2017)... ... February 24, 2017 , ... A study recently ... in an ambulatory surgery center (ASC) with satisfactory clinical and patient-reported outcomes, when ... studies. , Jake Lubinski, president of AxioMed, commented on the recent publication, ...
(Date:2/24/2017)... Feb. 24, 2017 Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... to participate in its previously announced rights offering ... shares of common stock and Series C Convertible ... listed warrants. As previously announced, ...
(Date:2/24/2017)... Feb. 24, 2017  Driven by consumers, preference ... now the fastest growing categories, finds the recently ... in Personal Care: Multi-regional Market Analysis and Opportunities ... consulting firm Kline. "Biotechnology actives are ... them more effective for skin and hair care ...
Breaking Biology Technology:
Cached News: